Merck Stock Forecast for 2022 - 2025 - 2030
Updated on 12/02/2022
Merck Stock Forecast and Price Target
The average price target of $110.00 for Merck's stock set by nineteen distinguished analysts in recent weeks would represent a potential upside of approximately 0.18% from the last closing price in December, 2022 if reached by the end of the year. This potential increase is based on a high estimate of $125.00 and a low estimate of $97.00. If you want to buy MRK stock, it might be a good idea to look at its competitors too.
0.18% Upside
Merck Fair Value Forecast for 2022 - 2025 - 2030
In the last three years, Merck's Price has grown, increasing from $65.71 to $91.14 – a growth of 38.71%. The next year looks promising for Merck, with analysts predicting Fair Value of $110.22 – an increase of 20.93%. Over the next nine years, experts anticipate that Merck's Fair Value will grow at a rate of 25.91%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
11
|
$178.74 | $181.36 | 0.98% |
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$370.33 | $333.19 | 5.85% |
| ABBV Stock Forecast | AbbVie | Outperform |
7
|
$161.63 | $164.23 | -1.94% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
18
|
£112.00 | £136.08 | 28.85% |
| DHR Stock Forecast | Danaher | Outperform |
16
|
$274.54 | $320.15 | 14.74% |
Merck Revenue Forecast for 2022 - 2025 - 2030
In the last three years, Merck's Revenue has grown, increasing from $42.29B to $48.70B – a growth of 15.16%. The next year looks promising for Merck, with analysts predicting Revenue of $57.19B – an increase of 17.43%. Over the next nine years, experts anticipate that Merck's Revenue will grow at a rate of 5.67%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb | Outperform |
2
|
$80.88 | $79.05 | 2.50% |
| AMGN Stock Forecast | Amgen | Hold |
7
|
$285.94 | $246.51 | -9.77% |
| GILD Stock Forecast | Gilead Sciences | Outperform |
9
|
$87.90 | $69.65 | -7.85% |
Merck Dividend per Share Forecast for 2022 - 2025 - 2030
In the last three years, Merck's Dividend per Share has grown by 35.42%, from $1.92 to $2.60. For the next year, analysts are expecting Dividend per Share to reach $2.85 – an increase of 9.62%. Over the next nine years, experts predict that Dividend per Share will grow by 23.08%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| CSL Stock Forecast | CSL | Outperform |
16
|
$298.66 | $228.01 | -28.44% |
| GE Stock Forecast | General Electric | Outperform |
17
|
$85.26 | $94.11 | 5.56% |
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
17
|
$250.83 | $272.08 | 8.04% |
Merck Free Cash Flow Forecast for 2022 - 2025 - 2030
In the last three years, Merck's Free Cash Flow has grown by 16.30%, rising from $8.31B to $9.66B. For next year, analysts predict Free Cash Flow of $15.51B, which would mean an increase of 60.52%. Over the next nine years, experts predict that Merck's Free Cash Flow will grow at a rate of 64.45%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| GSK Stock Forecast | GSK | Outperform |
16
|
£14.15 | £16.08 | 14.13% |
| MMM Stock Forecast | 3M | Hold |
16
|
$125.99 | $147.79 | 1.20% |
| BAYN Stock Forecast | Bayer | Outperform |
7
|
55.03€ | 67.79€ | 43.56% |
Merck Net Income Forecast for 2022 - 2025 - 2030
In the last three years, Merck's Net Income has grown from $6.22B to $13.05B – a 109.79% increase. Next year, analysts are expecting Net Income to reach $18.42B – an increase of 41.16%. Over the next nine years, the forecast is for Net Income to grow by 29.43%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| A Stock Forecast | Agilent Technologies | Outperform |
17
|
$156.12 | $157.63 | 3.77% |
| BAS Stock Forecast | BASF | Outperform |
11
|
47.86€ | 78.27€ | 14.92% |
| IDXX Stock Forecast | IDEXX Laboratories | Outperform |
16
|
$439.17 | $531.75 | 5.88% |
Merck EBITDA Forecast for 2022 - 2025 - 2030
In the last three years, Merck's EBITDA has grown by 29.80%, rising from $14.62B to $18.98B. For next year, analysts predict EBITDA of $24.07B, which would mean an increase of 26.84%. In 2030, professionals predict that Merck's EBITDA will decrease by 3.86%, to $18.25B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ILMN Stock Forecast | Illumina | Outperform |
16
|
$220.86 | $258.00 | 14.33% |
| ALC Stock Forecast | Alcon | Outperform |
15
|
CHF65.48 | CHF0.00 | 29.15% |
| 4503 Stock Forecast | Astellas Pharma | Outperform |
18
|
¥2.13k | ¥0.00 | 12.83% |
Merck EBIT Forecast for 2022 - 2025 - 2030
In the last three years, Merck's EBIT has grown, rising from $10.10B to $15.86B – a growth of 56.97%. In the next year, analysts believe that EBIT will reach $21.68B – an increase of 36.73%. For the next nine years, the forecast is for EBIT to grow by 23.04%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| BAX Stock Forecast | Baxter International | Outperform |
17
|
$52.38 | $65.40 | 22.18% |
| 4523 Stock Forecast | Eisai | Hold |
18
|
¥9.78k | ¥0.00 | -32.48% |
| HOLX Stock Forecast | Hologic | Outperform |
8
|
$76.99 | $77.25 | -1.29% |
Merck EPS Price Prediction Forecast for 2022 - 2025 - 2030
In the last three years, Merck's EPS has grown, increasing from $4.34 to $6.02 – a growth of 38.71%. The next year looks promising for Merck, with analysts predicting EPS of $7.28 – an increase of 20.93%. Over the next nine years, experts anticipate that Merck's EPS will grow at a rate of 25.91%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| INCY Stock Forecast | Incyte | Outperform |
9
|
$80.68 | $95.69 | 1.64% |
| FRE Stock Forecast | Fresenius SE & Co. KGaA | Outperform |
18
|
26.51€ | 50.04€ | 24.48% |
| AKZA Stock Forecast | Akzo Nobel N.V. | Outperform |
18
|
67.40€ | 113.10€ | 60.98% |